Lyra Therapeutics, Inc.

NasdaqGM:LYRA Rapport sur les actions

Capitalisation boursière : US$16.9m

Lyra Therapeutics Gestion

Gestion contrôle des critères 2/4

We currently do not have sufficient information about the CEO.

Informations clés

Maria Palasis

Directeur général

US$1.8m

Rémunération totale

Pourcentage du salaire du PDG32.7%
Durée du mandat du directeur général9.8yrs
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction2.3yrs
Durée moyenne du mandat des membres du conseil d'administration4.1yrs

Mises à jour récentes de la gestion

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Jul 05

Lyra Therapeutics: Progress In The Clinic

May 18

A First Look At Lyra Therapeutics

Apr 21

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04
We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05
How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11
Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

Analyse de la rémunération des PDG

Comment la rémunération de Maria Palasis a-t-elle évolué par rapport aux bénéfices de Lyra Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$101m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$2mUS$583k

-US$63m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$61m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$583k

-US$55m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$48m

Dec 31 2021US$2mUS$552k

-US$44m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$4mUS$471k

-US$22m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$843kUS$388k

-US$17m

Rémunération vs marché: Maria's total compensation ($USD1.79M) is above average for companies of similar size in the US market ($USD655.65K).

Rémunération et revenus: Maria's compensation has increased whilst the company is unprofitable.

PDG

Maria Palasis (59 yo)

9.8yrs

Titularisation

US$1,785,375

Compensation

Dr. Maria Palasis, Ph D, serves as Director at PanTher Therapeutics, Inc. since June 2021. Dr. Palasis has been Chief Executive Officer, President and Director of Lyra Therapeutics, Inc. since January 2015...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Harlan Waksal
Executive Chairman2.8yrsUS$625.06k0.40%
$ 67.8k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79mpas de données
Carmichael Roberts
Co-Founderno datapas de donnéespas de données
Jason Cavalier
CFO, Treasurer & Secretary3.2yrsUS$1.07mpas de données
Ray Knox
Vice President of Operationsno datapas de donnéespas de données
Ronan O'Brien
Chief Legal Officer1.1yrspas de donnéespas de données
Vineeta Belanger
Senior Vice President of Clinical Affairsno datapas de donnéespas de données
Robert Richard
Senior Vice President of Technical Operations1.8yrsUS$666.79kpas de données
Robert Kern
Chief Clinical Advisor3.8yrspas de donnéespas de données
Gloria Cosgrove
Senior Vice President of Quality1.8yrspas de donnéespas de données
Allison Nance
Senior Vice President of Regulatory Affairs1.8yrspas de donnéespas de données
Elazer Edelman
VP of Finance & Riskno datapas de donnéespas de données

2.3yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Gestion expérimentée: LYRA's management team is considered experienced (2.3 years average tenure).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Harlan Waksal
Executive Chairman2.8yrsUS$625.06k0.40%
$ 67.8k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79mpas de données
James Tobin
Lead Independent Director2.7yrsUS$152.31k0%
$ 0
W. Smith
Independent Director5yrsUS$123.81k0%
$ 0
George Whitesides
Member of Scientific Advisory Board4.1yrsUS$333.93kpas de données
C. Merrifield
Independent Director5.2yrsUS$113.06k0.017%
$ 2.9k
Robert Langer
Member of Scientific Advisory Board4.1yrsUS$19.36kpas de données
Michael Dake
Member of Medical Advisory Boardno datapas de donnéespas de données
William Gray
Member of Medical Advisory Boardno datapas de donnéespas de données
Mahmood Razavi
Member of Medical Advisory Boardno datapas de donnéespas de données
Gary Ansel
Member of Medical Advisory Boardno datapas de donnéespas de données
I. Baumgartner
Member of Medical Advisory Boardno datapas de donnéespas de données

4.1yrs

Durée moyenne de l'emploi

73yo

Âge moyen

Conseil d'administration expérimenté: LYRA's board of directors are considered experienced (4.1 years average tenure).